Andy Provencher spent a year searching for the cause of his exhausting symptoms before a physician's assistant suggested a ...
Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal ...